Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Widemann Website

Brigitte C. Widemann, M.D.

Selected Publications

1)  Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, Salzer W, Gillespie A, Baldwin A, Derdak J, Widemann B.
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Pediatr Blood Cancer. 60: 59-64, 2013.
[Journal]
2)  Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
J. Clin. Invest. 123: 340-7, 2013.
[Journal]
3)  Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Pediatr Blood Cancer. 60: 396-401, 2013.
[Journal]
4)  Avery RA, Dombi E, Hutcheson KA, Acosta MT, Baldwin AM, Madigan WP, Gillespie A, Fitzgibbon EJ, Packer RJ, Widemann BC.
Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas.
Am. J. Ophthalmol. [Epub ahead of print], 2013.
[Journal]
5)  Lodish M, Dagalakis U, Chen CC, Sinaii N, Whitcomb P, Aikin A, Dombi E, Marcus L, Widemann B, Fox E, Chuk M, Balis F, Wells S, Stratakis CA.
(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.
J. Clin. Endocrinol. Metab. 97: E207-12, 2012.
[Journal]
6)  Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Pediatr Blood Cancer. 59: 865-9, 2012.
[Journal]
7)  Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM.
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children"s Oncology Group Phase I Consortium report.
Clin. Cancer Res. 18: 6011-22, 2012.
[Journal]
8)  Lodish MB, Dagalakis U, Sinaii N, Bornstein E, Kim A, Lokie KB, Baldwin AM, Reynolds JC, Dombi E, Stratakis CA, Widemann BC.
Bone mineral density in children and young adults with neurofibromatosis type 1.
Endocr. Relat. Cancer. 19: 817-25, 2012.
[Journal]
9)  Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF.
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.
Orphanet J Rare Dis. 7: 75, 2012.
[Journal]
10)  Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, Meyers PA, Widemann BC, Tsokos M, Mackall CL.
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
J. Clin. Oncol. 30: 4141-7, 2012.
[Journal]
11)  Martin S, Wolters P, Baldwin A, Gillespie A, Dombi E, Walker K, Widemann B.
Social-emotional Functioning of Children and Adolescents With Neurofibromatosis Type 1 and Plexiform Neurofibromas: Relationships With Cognitive, Disease, and Environmental Variables.
J Pediatr Psychol. 37: 713-24, 2012.
[Journal]
12)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
[Journal]
13)  Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, Zalewski C, Kim HJ, Bishop R, Hill S, Paul SM, Kicker P, Phillips Z, Dolan JG, Widemann B, Jayaprakash N, Pucino F, Stone DL, Chapelle D, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R.
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes.
Arthritis Rheum. 64: 2375-86, 2012.
[Journal]
14)  Kim A, Dombi E, Solomon JM, Fox E, Balis FM, Widemann BC.
Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.
Clin Cancer Res. 17: 5982-90, 2011.
[Journal]
15)  Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner V, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M.
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Am. J. Med. Genet. A. 158A: 24-41, 2011.
[Journal]
16)  Martin S, Gillespie A, Wolters PL, Widemann BC.
Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute.
Contemp Clin Trials. 32: 10-5, 2011.
[Journal]
17)  Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM.
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 56: 226-33, 2011.
[Journal]
18)  Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC.
Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.
Neurology. 76: 265-72, 2011.
[Journal]
19)  Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim M, Kim A, Widemann BC, Cripe TP, Ratner N.
Preclincial testing of Sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Pediatr Blood Cancer. 58: 173-80, 2011.
[Journal]
20)  Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC.
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Cancer Chemother Pharmacol. 69: 247-52, 2011.
[Journal]
21)  Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM.
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
J. Clin. Oncol. 28: 5174-81, 2010.
[Journal]
22)  Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC.
Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome.
J Clin Oncol. 28: 3979-86, 2010.
[Journal]
23)  Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E.
Pediatric phase I trial design using maximum target inhibition as the primary endpoint.
J. Natl. Cancer Inst. 102: 909-12, 2010.
[Journal]
24)  Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM.
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
Cancer Chemother. Pharmacol. 66: 737-43, 2010.
[Journal]
25)  Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC.
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Clin. Cancer Res. 16: 750-4, 2010.
[Journal]
26)  Chuk MK, Cole DE, McCully C, Loktionova NA, Pegg AE, Parker RJ, Pauly G, Widemann BC, Balis FM, Fox E.
Plasma and CNS pharmacokinetics of O(4)-benzylfolic acid (O (4)BF) and metabolite in a non-human primate model.
Cancer Chemother Pharmacol. 67: 1291-7, 2010.
[Journal]
27)  Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, Widemann BC.
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Invest New Drugs. 30: 524-8, 2010.
[Journal]
28)  Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, Balis FM, Widemann BC.
Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Neurology. 73: 1273-9, 2009.
[Journal]
29)  Balis FM, Fox E, Widemann BC, Adamson PC.
Clinical drug development for childhood cancers.
Clin. Pharmacol. Ther. 85: 127-9, 2009.
[Journal]
30)  Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M.
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Clin. Cancer Res. 15: 5032-9, 2009.
[Journal]
31)  Widemann BC.
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Curr Oncol Rep. 11: 322-8, 2009.
[Journal]
32)  Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E.
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
J. Clin. Oncol. 27: 550-6, 2009.
[Journal]
33)  Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Clin. Cancer Res. 15: 7361-7, 2009.
[Journal]
34)  Kim A, Balis FM, Widemann BC.
Sorafenib and sunitinib.
Oncologist. 14: 800-5, 2009.
[Journal]
35)  Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Clin. Cancer Res. 14: 1111-5, 2008.
[Journal]
36)  Mautner V, Asuagbor FA, Dombi E, Funsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM.
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
Neuro-oncology. 10: 593-8, 2008.
[Journal]
37)  Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
Oncologist. 13: 679-89, 2008.
[Journal]
38)  Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Blood. 111: 566-73, 2008.
[Journal]
39)  Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A.
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.
J. Neurooncol. 87: 165-71, 2008.
[Journal]
40)  Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, Korf BR, Babovic-Vuksanovic D, Packer RJ, Belasco J, Goldman S, Jakacki R, Kieran M, Steinberg SM, Widemann BC.
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Neurology. 68: 643-7, 2007.
[Journal]
41)  Babovic-Vuksanovic D, Widemann BC, Dombi E, Gillespie A, Wolters PL, Toledo-Tamula MA, O'Neill BP, Fox E, MacDonald T, Beck H, Packer RJ.
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
Pediatr. Neurol. 36: 293-300, 2007.
[Journal]
42)  Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Clin. Cancer Res. 12: 4882-7, 2006.
[Journal]
43)  Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM.
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
J. Clin. Oncol. 24: 507-16, 2006.
[Journal]
44)  Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM.
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
Cancer Chemother. Pharmacol. 58: 343-7, 2006.
[Journal]
45)  Widemann BC, Adamson PC.
Understanding and managing methotrexate nephrotoxicity.
Oncologist. 11: 694-703, 2006.
[Journal]
46)  Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, Clark G, Gantz SB, Venzon D, Zujewski J.
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Clin Cancer Res. 11: 1247-52, 2005.
[Journal]
47)  Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM.
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
J. Clin. Oncol. 23: 7646-53, 2005.
[Journal]
48)  Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC.
The bioavailability of oral methotrexate in children with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 40: 445-9, 2005.
[Journal]
49)  Solomon J, Warren K, Dombi E, Patronas N, Widemann B.
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging.
Comput Med Imaging Graph. 28: 257-65, 2004.
[Journal]
50)  Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC.
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Cancer. 100: 2222-32, 2004.
[Journal]
51)  Widemann BC.
Merlin PAKs a punch.
Cancer J. 10: 8-11, 2004.
[Journal]
52)  Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM.
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
Cancer Chemother Pharmacol. 53: 482-8, 2004.
[Journal]
53)  Widemann BC, Balis FM, Shalabi A, Boron M, O'Brien M, Cole DE, Jayaprakash N, Ivy P, Castle V, Muraszko K, Moertel CL, Trueworthy R, Hermann RC, Moussa A, Hinton S, Reaman G, Poplack D, Adamson PC.
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
J Natl Cancer Inst. 96: 1557-9, 2004.
[Journal]
54)  Salzer W, Steinberg SM, Liewehr DJ, Freifeld A, Balis FM, Widemann BC.
Evaluation and treatment of fever in the non-neutropenic child with cancer.
J Pediatr Hematol Oncol. 25: 606-12, 2003.
[Journal]
55)  Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
J Clin Oncol. 21: 1866-73, 2003.
[Journal]
56)  Widemann BC, Boos J.
Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Gunzburg an der donau.
Klin Padiatr. 214: 236-9, 2002.
[Journal]
57)  Adamson PC, Widemann BC, Reaman GH, Seibel NL, Murphy RF, Gillespie AF, Balis FM.
A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
Clin Cancer Res. 7: 3034-9, 2001.
[Journal]
58)  Lowe ES, Kitchen BJ, Erdmann G, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Woods W, Franklin J, Widemann BC, Balis FM, Murphy RF, Adamson PC.
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
Cancer Chemother Pharmacol. 47: 199-205, 2001.
[Journal]
59)  Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS, McCully C, Hawkins M, Adamson PC.
Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
J Pharmacol Exp Ther. 294: 894-901, 2000.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 5/3/2013.